Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors

NCT02650635 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02650635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02650635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
February 5, 2016
Completion date
June 1, 2017
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, metastatic pancreatic adenocarcinoma, recurrent breast carcinoma, recurrent colorectal carcinoma, recurrent melanoma of the skin, recurrent non-small cell lung carcinoma, recurrent pancreatic carcinoma, recurrent renal cell carcinoma, solid neoplasm, stage iv breast cancer, stage iv non-small cell lung cancer, stage iv renal cell cancer, stage iv skin melanoma, stage iva colorectal cancer, stage iva pancreatic cancer, stage ivb colorectal cancer, stage ivb pancreatic cancer